Trial Profile
PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 16 Apr 2023 Status changed from recruiting to discontinued. Due to lack of results, study has been early terminated.
- 20 Jan 2018 Results of pool data from two parallel phases II trials (NCT02677038 and NCT02511223) assessing the efficacy of olaparib in advanced PDAC with BRCAness, were presented at the 2018 Gastrointestinal Cancers Symposium.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.